CN102076351A - 损伤组织的功能性再生促进药物 - Google Patents

损伤组织的功能性再生促进药物 Download PDF

Info

Publication number
CN102076351A
CN102076351A CN2009801252435A CN200980125243A CN102076351A CN 102076351 A CN102076351 A CN 102076351A CN 2009801252435 A CN2009801252435 A CN 2009801252435A CN 200980125243 A CN200980125243 A CN 200980125243A CN 102076351 A CN102076351 A CN 102076351A
Authority
CN
China
Prior art keywords
cells
protein
bone marrow
tissue
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801252435A
Other languages
English (en)
Chinese (zh)
Inventor
玉井克人
山崎尊彦
知野刚直
金田安史
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomix Co Ltd
University of Osaka NUC
Original Assignee
Osaka University NUC
Genomix Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Genomix Co Ltd filed Critical Osaka University NUC
Publication of CN102076351A publication Critical patent/CN102076351A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN2009801252435A 2008-04-30 2009-04-30 损伤组织的功能性再生促进药物 Pending CN102076351A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008119324 2008-04-30
JP2008-119324 2008-04-30
PCT/JP2009/058519 WO2009133940A1 (ja) 2008-04-30 2009-04-30 損傷組織の機能的再生促進医薬

Publications (1)

Publication Number Publication Date
CN102076351A true CN102076351A (zh) 2011-05-25

Family

ID=41255155

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801252435A Pending CN102076351A (zh) 2008-04-30 2009-04-30 损伤组织的功能性再生促进药物

Country Status (10)

Country Link
US (1) US20110097309A1 (enExample)
EP (1) EP2301560A4 (enExample)
JP (3) JP5814549B2 (enExample)
KR (1) KR20110027665A (enExample)
CN (1) CN102076351A (enExample)
AU (1) AU2009240885A1 (enExample)
BR (1) BRPI0911436A2 (enExample)
CA (1) CA2722906A1 (enExample)
RU (1) RU2010148785A (enExample)
WO (1) WO2009133940A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108367068A (zh) * 2015-09-14 2018-08-03 拉瓦尔大学 用于治疗白血病的抗-s100a8
CN111494423A (zh) * 2020-04-22 2020-08-07 上海市东方医院（同济大学附属东方医院） 一种干细胞组合物及其应用和干细胞滴液
WO2023174447A1 (zh) * 2022-03-14 2023-09-21 陈小松 间充质干细胞创面修复优势功能亚群及其鉴定和应用
CN120837666A (zh) * 2025-09-22 2025-10-28 中国人民解放军军事科学院军事医学研究院 靶向巨噬细胞s100a9蛋白在肝纤维化治疗中的应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110027665A (ko) * 2008-04-30 2011-03-16 가부시키가이샤 제노믹스 손상조직의 기능적 재생 촉진 의약
RU2519714C2 (ru) * 2008-04-30 2014-06-20 Дженомикс Ко., Лтд. Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток
WO2009133943A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
CN102711777B (zh) * 2009-10-28 2015-04-15 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
JP5852773B2 (ja) * 2010-06-01 2016-02-03 ピアス株式会社 骨髄間葉系幹細胞の誘引剤の製造方法、骨髄間葉系幹細胞の誘引方法、及び、骨髄間葉系幹細胞の誘引剤を製造するための使用
DK2703487T3 (en) 2011-04-26 2018-09-10 Genomix Co Ltd TIME TO INDUCTION Tissue Regeneration and its Use
RU2647467C2 (ru) 2012-10-25 2018-03-15 Дженомикс Ко., Лтд. Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
EP2913059B1 (en) * 2012-10-25 2018-04-11 Genomix Co., Ltd. Novel method for treating spinal cord injury using hmgb1 fragment
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
AU2018257071B2 (en) 2017-04-25 2021-11-11 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
CN110709506A (zh) * 2017-07-18 2020-01-17 株式会社资生堂 间充质干细胞导引剂
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
EP3719117A4 (en) 2017-12-01 2021-11-03 Stemrim Inc. EECTODERMAL MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING THEM
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
EP3756679A1 (en) * 2019-06-28 2020-12-30 Université de Genève Compositions for use in the treatment of insulin deficiency conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2325226A1 (en) * 1999-11-17 2001-05-17 Switch Biotech Ag Use of polypeptides or nucleic acids encoding these for the diagnosis or treatment of skin disorders, and their use for the identification of pharmacologically active substances
WO2002088181A2 (en) * 2001-04-30 2002-11-07 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
CN1518604A (zh) * 2001-05-09 2004-08-04 克利夫兰大学医院 用新型基因标记、与之相关的方法和组合物来评测皮肤的紫外辐射损伤
WO2006047820A1 (en) * 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
DK1257632T3 (da) * 2000-02-24 2008-01-28 Xcyte Therapies Inc Samtidig stimulering og opkoncentrering af celler
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
EP1459759A4 (en) * 2001-11-19 2007-08-29 Kyowa Hakko Kogyo Kk MEDICAMENT FOR THE MOBILIZATION OF PLURIPOTENTIAL STEM CELLS FROM TISSUE IN THE PERIPHERAL BLOOD
ATE424416T1 (de) * 2002-07-03 2009-03-15 San Raffaele Centro Fond Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
DE60327075D1 (de) * 2002-07-05 2009-05-20 Univ Laval Der entzündungsreaktionen
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
US7632802B2 (en) * 2003-03-28 2009-12-15 UNIVERSITé LAVAL S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
US20090062187A1 (en) * 2004-07-20 2009-03-05 Marco Bianchi Use of Hmgb1 for Wound Healing
KR100593397B1 (ko) * 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
JP5308161B2 (ja) * 2006-10-30 2013-10-09 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
RU2519714C2 (ru) * 2008-04-30 2014-06-20 Дженомикс Ко., Лтд. Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток
WO2009133943A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
KR20110027665A (ko) * 2008-04-30 2011-03-16 가부시키가이샤 제노믹스 손상조직의 기능적 재생 촉진 의약

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2325226A1 (en) * 1999-11-17 2001-05-17 Switch Biotech Ag Use of polypeptides or nucleic acids encoding these for the diagnosis or treatment of skin disorders, and their use for the identification of pharmacologically active substances
WO2002088181A2 (en) * 2001-04-30 2002-11-07 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
CN1518604A (zh) * 2001-05-09 2004-08-04 克利夫兰大学医院 用新型基因标记、与之相关的方法和组合物来评测皮肤的紫外辐射损伤
WO2006047820A1 (en) * 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108367068A (zh) * 2015-09-14 2018-08-03 拉瓦尔大学 用于治疗白血病的抗-s100a8
CN108367068B (zh) * 2015-09-14 2021-08-03 拉瓦尔大学 用于治疗白血病的抗-s100a8
CN111494423A (zh) * 2020-04-22 2020-08-07 上海市东方医院（同济大学附属东方医院） 一种干细胞组合物及其应用和干细胞滴液
WO2023174447A1 (zh) * 2022-03-14 2023-09-21 陈小松 间充质干细胞创面修复优势功能亚群及其鉴定和应用
CN120837666A (zh) * 2025-09-22 2025-10-28 中国人民解放军军事科学院军事医学研究院 靶向巨噬细胞s100a9蛋白在肝纤维化治疗中的应用

Also Published As

Publication number Publication date
JP5814549B2 (ja) 2015-11-17
US20110097309A1 (en) 2011-04-28
BRPI0911436A2 (pt) 2016-07-12
JP2016104790A (ja) 2016-06-09
AU2009240885A1 (en) 2009-11-05
JP2014139177A (ja) 2014-07-31
KR20110027665A (ko) 2011-03-16
EP2301560A1 (en) 2011-03-30
EP2301560A4 (en) 2012-05-09
JP5960735B2 (ja) 2016-08-02
WO2009133940A1 (ja) 2009-11-05
AU2009240885A2 (en) 2011-01-27
JPWO2009133940A1 (ja) 2011-09-01
CA2722906A1 (en) 2009-11-05
RU2010148785A (ru) 2012-06-10

Similar Documents

Publication Publication Date Title
JP5960735B2 (ja) 損傷組織の機能的再生促進医薬
US20240050460A1 (en) Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues
CN102711777B (zh) 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
CN102083962B (zh) 生物体内功能性细胞的高效采集方法
JP6002727B2 (ja) 末梢循環への骨髄由来多能性幹細胞動員薬
AU2014200688C1 (en) Pharmaceuticals that promote functional regeneration of damaged tissues
HK1156211A (en) Pharmaceutical agent for promoting the functional regeneration of damaged tissue
HK1126685A (en) Pharmaceuticals that promote functional regeneration of damaged tissues

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110525